We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Nevro Corp (NVRO) USD0.001

Sell:$87.23 Buy:$87.24 Change: $0.79 (0.92%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.79 (0.92%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.79 (0.92%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nevro Corp. is a global medical device company that provides solutions for the treatment of chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform. Its Senza System, Senza II System, and the Senza Omnia System are the SCS systems that delivers Nevro's 10 kilohertz (kHz) therapy. The Senza system is focused on creating traditional low frequency electrical impulses and its HF10 therapy, which allows for pain relief without paresthesia. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. The HF10 therapy delivers waveforms at 10,000 Hertz (Hz) pulse rate with a statistically driven and clinically verified programming algorithm.

Contact details

1800 Bridge Pkwy
United States
+1 (650) 2510005

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.01 billion
Shares in issue:
34.90 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • D. Keith Grossman
    Chairman of the Board, President, Chief Executive Officer
  • Roderick MacLeod
    Chief Financial Officer
  • Lori Ciano
    Chief Human Resource Officer
  • Christopher Christoforou
    Vice President - Technical Operations
  • Donald Middlebrook
    Vice President - Clinical, Regulatory and Quality
  • Kashif Rashid
    General Counsel, Corporate Secretary
  • David Caraway
    Chief Medical Officer
  • Niamh Pellegrini
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.